Long-term follow-up of people with multiple myeloma previously treated with GC012F
Follows people with multiple myeloma who previously received GC012F over the long term.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Renji Hospital, Shanghai Jiaotong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT07833046
- Record updated
- 9 November 2026
- Original description
This is an open-label, multicenter, observational study (non-interventional study) to evaluate the long-term safety, efficacy, and in vivo pharmacokinetic persistence of CAR-T cells in subjects treated with GC012F InjectionRead full original descriptionShow less
Long-term Follow-up Study to Evaluate Subjects With Multiple Myeloma Treated With GC012F Injection
This is an open-label, multicenter, observational study (non-interventional study) to evaluate the long-term safety, efficacy, and in vivo pharmacokinetic persistence of CAR-T cells in subjects treated with GC012F Injection
Inclusion: Patients with multiple myeloma who previously received GC012F Injection infusion in an investigator-initiated trial; Patients who have completed the safety and efficacy follow-up of the main study or withdrawn early; Patients who agree to sign the informed consent form and are willing and able to comply with the visits, laboratory tests, and other protocol requirements specified in the study visit schedule.
Exclusion: Patients with multiple myeloma who participated in the main study but withdrew early without receiving GC012F Injection; Patients who refuse to undergo long-term follow-up after GC012F Injection treatment.